Ligand (LGND) Breakout! Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout!

LGND 190.12

-2.5%

Dec 30 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: bob zagorin who wrote (29275)	9/13/1999 5:56:00 PM
From: Henry Niman	Read Replies (1) of 32384

Tonight LGND released details of a new agreement with Roche concerning using of daclizumab, a monoclonal antibody directed against the IL-2 Receptor. I assume that this is the rumored patent infringement which would add icing to the SRGN deal. For some time there had been a rumor that LGND would get additional benefits through enforcement of patents licensed by SRGN. Since Roche is agreeing to pay $2.5 million for sales BEFORE this agreement, it would seem that their Zenapax product had some interference with the "Strom Patents". It's rather ironic that LGND is collecting money from Roche. In the past some had speculated on the "Roche patent" causing a problem with Panretin. Although the patents and molecules are totally unrelated, tonight's press release makes it clear who is paying whom for patent infringements in this case.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next